Carlyle and SK Capital to Acquire bluebird bio
1 minute read | March.07.2025
bluebird bio (NASDAQ: BLUE), a biotechnology company engaged in the research, development and commercialization of potentially curative gene therapies for severe genetic diseases, recently announced that it has entered into a definitive agreement to be acquired in a take private transaction by Beacon Parent Holdings, L.P. in collaboration with global investment firms Carlyle Group and SK Capital together with a team of highly experienced biotech executives, including David Meek, Robert Mulroy, and Debasish Roychowdhury. The transaction will also provide bluebird primary capital to scale its commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Orrick represented Beacon Parent Holdings, L.P. as well as Carlyle and SK Capital in the transaction.
Gregg Griner, Tony Chan and Albert Vanderlaan led the Orrick team, which included Kayla Southworth, Kyle Zhu, Lois Emmanuel, Marley Brison Henchar, Jimmy Frost, Bailey Higgs, Dolph Hellman, Andy Bloom, Jason Flaherty, Keith Tidwell, Sharon Zhou, Georgia Ravitz, Amy Joseph, Thora Johnson, Shari Esfahani, Melania Jankowski, Alyssa Wolfington, David Sharrow, Tiffany Chiu Leung, Craig Falls, Victoria Newbold, Kristin Petersen, Alexa Steranko, Eric Wall, Kimberly Loocke, Alex Talarides, Richard Martinelli, Jessica Stern, Lisa Lupion, Noel Pacheco, Millay Kogan and Neetu Ahlawat.